iBio Inc. announced research results showing that a single administration of the candidate drug IBIO-610 in an obese non-human primate model achieved nearly complete inhibition of active activin E for up to eight weeks.

iBio Inc. announced research results showing that a single administration of the candidate drug IBIO-610 in an obese non-human primate model achieved nearly complete inhibition of active activin E for up to eight weeks.

老虎证券2026/07/01 11:21

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This data reveals that the therapy exhibits lasting pharmacological activity in targeting this specific pathway.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

iBio Inc. announced research results showing that a single administration of the candidate drug IBIO-610 in an obese non-human primate model achieved nearly complete inhibition of active activin E for up to eight weeks.

You may also like

Crypto prices